| Abstract P250 – Table 1. Clinical‐demographic comparison according to the regimen received (homologous vs heterologous prime‐boost). | |||
|---|---|---|---|
| Variable | Homologous (n = 79) | Heterologous (n = 21) | p |
| Median age, years (IQR) | 47 (37 to 53) | 54 (51 to 59) | 0.019 |
| Sex, n (%) | |||
| Female | 25 (32) | 7 (33) | 0.155 |
| Male | 54 (68) | 14 (67) | |
| Median CD4+ T‐cell count, cells/mm3 (IQR) | 620 (447 to 791) | 620 (571 to 815) | 0.171 |
| Plasma HIV‐RNA <20 copies/mL, n (%) | 75 (95) | 21 (100) | 0.176 |
| History of COVID‐19, n (%) | |||
| No | 70 (89) | 20 (95) | 0.907 |
| Yes | 9 (11) | 1 (5) | |
| Median days between second dose and Ab measurement (IQR) | 37 (32 to 50) | 40 (36 to 50) | 0.381 |
| Ab titers ≥1 U/mL (POSITIVE), n (%) | 76 (96) | 21 (100) | 0.590 |
| Median Ab titers, U/mL (IQR) | 30.7 (9 to 100) | 150 (78 to 150) | 0.005 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.